In contrast to other agents that suppress CIPN in preclinical models (for review, see Flatters et al., 2017), a 2 week course of dosing with an HDAC6 inhibitor persistently reverses peripheral neuropathy induced by cisplatin and paclitaxel (Krukowski et al., 2017; Ma et al., 2019; J. Zhang et al., 2022). Here, HDAC6 is linked to peripheral neuropathy.